Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD137 monoclonal antibody PE0116

A human immunoglobulin G4 (IgG4) agonistic monoclonal antibody directed against the inducible T-cell costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 monoclonal antibody PE0116 is selectively activated in the tumor microenvironment (TME), and targets, binds to, crosslinks and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces T-cell proliferation, cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity to promote anti-tumor immunity.
Synonym:anti-4-1BB monoclonal antibody PE0116
Code name:PE 0116
PE-0116
PE0116
Search NCI's Drug Dictionary